Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.

Kuramitsu Y, Tominaga W, Baron B, Tokuda K, Wang Y, Kitagawa T, Nakamura K.

Anticancer Res. 2013 Jun;33(6):2557-60.

PMID:
23749908
2.

Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines.

Kuramitsu Y, Miyamoto H, Tanaka T, Zhang X, Fujimoto M, Ueda K, Tanaka T, Hamano K, Nakamura K.

Proteomics. 2009 Nov;9(22):5078-89. doi: 10.1002/pmic.200800284.

PMID:
19771552
3.

Altered protease-activated receptor-1 expression and signaling in a malignant pleural mesothelioma cell line, NCI-H28, with homozygous deletion of the β-catenin gene.

Fazzini A, D'Antongiovanni V, Giusti L, Da Valle Y, Ciregia F, Piano I, Caputo A, D'Ursi AM, Gargini C, Lucacchini A, Mazzoni MR.

PLoS One. 2014 Nov 3;9(11):e111550. doi: 10.1371/journal.pone.0111550. eCollection 2014.

4.

Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells.

Kuramitsu Y, Suenaga S, Wang Y, Tokuda K, Kitagawa T, Tanaka T, Akada J, Maehara S, Maehara Y, Nakamura K.

Anticancer Res. 2013 Aug;33(8):3133-6.

PMID:
23898070
5.

Dipalmitoleoyl-phosphatidylethanolamine induces apoptosis of NCI-H28 malignant mesothelioma cells.

Kaku Y, Tsuchiya A, Kanno T, Nakano T, Nishizaki T.

Anticancer Res. 2014 Apr;34(4):1759-64.

PMID:
24692707
6.

Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.

Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K.

Virchows Arch. 2013 Jan;462(1):83-93. doi: 10.1007/s00428-012-1344-6. Epub 2012 Nov 28.

PMID:
23187830
7.

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.

Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, Masachika E, Nishizaki T, Nakano T.

BMC Cancer. 2013 Apr 24;13:205. doi: 10.1186/1471-2407-13-205.

8.

Alterations in manganese, copper, and zinc contents, and intracellular status of the metal-containing superoxide dismutase in human mesothelioma cells.

Hasegawa S, Koshikawa M, Takahashi I, Hachiya M, Furukawa T, Akashi M, Yoshida S, Saga T.

J Trace Elem Med Biol. 2008;22(3):248-55. doi: 10.1016/j.jtemb.2008.05.001. Epub 2008 Jul 18.

PMID:
18755401
9.

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R.

Cancer Res. 2006 Jan 1;66(1):352-61.

10.

AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis.

Nogi Y, Kanno T, Nakano T, Fujita Y, Tabata C, Fukuoka K, Gotoh A, Nishizaki T.

Cell Physiol Biochem. 2012;30(1):61-74. doi: 10.1159/000339048. Epub 2012 Jun 8.

11.

Diarachidonoylphosphoethanolamine induces necrosis/necroptosis of malignant pleural mesothelioma cells.

Kaku Y, Tsuchiya A, Kanno T, Nakano T, Nishizaki T.

Cell Signal. 2015 Sep;27(9):1713-9. doi: 10.1016/j.cellsig.2015.05.007. Epub 2015 May 22.

PMID:
26004138
12.

TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.

Yuan BZ, Chapman J, Ding M, Wang J, Jiang B, Rojanasakul Y, Reynolds SH.

BMC Cancer. 2013 Mar 22;13:140. doi: 10.1186/1471-2407-13-140.

13.

Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.

Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S.

Oncol Res. 2006;16(5):235-43.

PMID:
17294804
14.

AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.

Sudo H, Tsuji AB, Sugyo A, Abe M, Hino O, Saga T.

Int J Oncol. 2014 Feb;44(2):530-8. doi: 10.3892/ijo.2013.2183. Epub 2013 Nov 20.

PMID:
24253341
15.

Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.

Eguchi R, Kubo S, Takeda H, Ohta T, Tabata C, Ogawa H, Nakano T, Fujimori Y.

Carcinogenesis. 2012 May;33(5):969-75. doi: 10.1093/carcin/bgs109. Epub 2012 Feb 21.

PMID:
22354875
16.

Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.

Kang Y, Ding M, Tian G, Guo H, Wan Y, Yao Z, Li B, Lin D.

Oncol Rep. 2013 Jul;30(1):313-9. doi: 10.3892/or.2013.2429. Epub 2013 Apr 26.

PMID:
23624653
17.

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.

Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F.

Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546. Epub 2013 Dec 17.

PMID:
24345738
18.

Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T.

Respir Med. 2011 Jan;105(1):137-42. doi: 10.1016/j.rmed.2010.10.010. Epub 2010 Oct 30.

19.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
20.

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N.

Ann Oncol. 2013 Dec;24(12):3128-35. doi: 10.1093/annonc/mdt412. Epub 2013 Oct 22.

PMID:
24148817

Supplemental Content

Support Center